Chair Prof. Ying Xu (AAAS Fellow and IEEE Fellow)

Southern University of Science and Technology, China

Ying Xu is a Chair Professor in the School of Medicine, Southern University of Science and Technology, China since January 2023. He is also a Cheungkong Scholar Chair Professor (2008 -) and Qianren Chair Professor (2012 -). Before that, he was a Regent Professor and the Georgia Research Alliance Eminent Scholar Chair in the Department of Biochemistry and Molecular Biology (2003 – 2022/12) and the Founding Director of the Institute of Bioinformatics, the University of Georgia, USA (2003-2011). He is an AAAS Fellow and an IEEE Fellow. He has been a computational biologist since 1993 when he joined the Oak Ridge National Laboratory to take part in the Human Genome Project, where he worked for ten years and moved up the career ladder from a research associate to a senior staff scientist and group leader. He has published over 400 research papers and five books, including the world's first monograph “Cancer Bioinformatics”. His H-Index is 73 with more than 21000 citations in scholar.google. He received his Ph.D. in theoretical computer science from the University of Colorado in 1991 and earlier degrees from Jilin University, China.

 

 

Prof. Qiang Li

Shenzhen University General Hospital, China

Prof. Qiang Li is a Professor, Chief Physician, MD, doctoral supervisor, and post-doctoral supervisor, serving as Director of the Department of Internal Medicine and Director of the Department of Endocrine and Metabolic Diseases. He has served as an editorial board member or deputy editor-in-chief of 12 national planning textbooks, including undergraduate Internal Medicine (8th–10th editions), eight-year Internal Medicine (3rd–4th editions), graduate Endocrine Internal Medicine (2nd–3rd editions), and resident physician Endocrine Division of Internal Medicine. He is the lead author of 3 expert consensus or guidelines and has participated in 20 guidelines or expert consensus documents. He has led and completed 12 National Natural Science Foundation projects as well as provincial and ministerial-level projects. He was awarded the first batch of second-level professors in Heilongjiang Province and has trained 116 postdoctoral, doctoral, and master's degree holders. He has also served as Vice President of the Endocrine Metabolism Branch of the Chinese Geriatrics Association, Vice Chairman of the Diabetes Professional Committee of the Chinese Medical Education Association, the 10th Standing Committee Member of the Endocrine Society of the Chinese Medical Association, and Standing Committee Member (1st–4th sessions) of the Endocrine Metabolism Branch of the Chinese Medical Doctor Association. He has been honored as an Excellent Teacher in Guangdong, Good Doctor in Guangdong, Famous Doctor of Lingnan, and Famous Doctor of Heilongjiang.

Speech Title: "Breakthrough in Continuous Glucose Monitoring (CGM) from 14 to 21 Days: Results of a Multicenter Clinical Trial"

Abstract: Objective: To evaluate the accuracy and safety of the 21-day continuous glucose monitoring system for dynamic glucose monitoring using venous blood glucose levels as the reference standard. Methods: A prospective, multicenter, single-arm target value clinical trial was carried out at three Chinese research centers. Diabetic subjects wore the TX-21 system, and venous blood glucose measured by an EKF glucose/lactate analyzer was the reference. Primary efficacy endpoints included 20/20% concordance rate, Clarke and Consensus Error Grid Analysis (A+B proportions), and mean absolute relative difference (MARD). Secondary endpoints covered other concordance rates, alarm accuracy, sensor performance, repeatability, lifespan, usability; safety endpoints were adverse events and device deficiencies. Results: 70 diabetic subjects (75.36% type 1, 24.64% type 2 diabetes) were enrolled, with 2173 valid CGM-EKF pairs collected. For primary efficacy endpoints, the 20/20% concordance rate with the reference value was 93.79% (95% CI lower limit: 92.69%), Clarke Error Grid Analysis A+B proportion 99.40% (95% CI lower limit: 98.98%), Consensus Error Grid Analysis A+B proportion 100% (95% CI lower limit: 99.83%), and MARD 8.225±2.493% (95% CI upper limit: 8.824%); all met the predefined target values. Secondary endpoints showed strong performance in concordance rates, hyperglycemia (99.26%) and hypoglycemia (96.41%) detection. The sensor was stable for 21 days (median lifespan) with 6.43% cumulative failure rate and good repeatability (PARD 7.590±8.761%); usability was rated good. 5 adverse events (5.71% incidence) occurred in 4 subjects, all unrelated to the device; no serious adverse events or device deficiencies were reported. Conclusion: The 21-day continuous glucose monitoring system TX-21 demonstrates favorable accuracy, stable performance, and reliable safety, with broad applicability across different types of diabetes and various blood glucose ranges.

 

 

Prof. Gang Liu

Huazhong University of Science and Technology, China (AIMBE Fellow)

 

Invited Speakers of ICPPS 2026

 

 

Prof. Sharadendu Bali

Teerthanker Mahaveer Medical College, India

Dr. Sharadendu Bali is a Professor of General Surgery at Teerthanker Mahaveer Medical College in Moradabad, India, combining 35 years of clinical experience with advanced interdisciplinary research. He earned his MBBS from Christian Medical College (1988), an MS from KMC, Manipal (1991), and joined the surgical faculty in 1997, achieving the rank of Professor in 2007. Bridging conventional medicine with translational science, he completed a PhD in Medical Biochemistry in 2023, focusing his doctoral research on lipid profiles and plant-based phytochemicals. An innovative researcher and entrepreneur, Dr. Bali has authored over 60 peer-reviewed publications in reputed journals and previously founded and managed a herbal pharmaceutical enterprise. His commitment to evidence-based complementary medicine is further demonstrated by four independently granted patents for therapeutic herbal confectionery formulations. Currently, besides his regular duties as Professor Surgery, Dr. Bali directs active, cutting-edge research initiatives targeting critical global health challenges: developing nanostructured lipid carriers for oncology treatments, investigating mechanisms to combat antimicrobial resistance (AMR), and evaluating nutrient bioaccessibility in herb-fortified traditional dietary systems.

Speech Title: "The Pharmacological and Public Health Significance of the Sacred Hydrology engineered by Sage Markandey at Besakih Temple complex using five metals"

Abstract: The culture of Bali Island is firmly believed by the local population to have been established by Rishi Markandeya. The connection between Rishi Markandeya from mainland India, and the island of Bali illustrates a long-lasting transmission of early Indian religious, cultural and health-promoting ideas across the seas. Through his establishment of Agama Tirtha, the holy ritual of water, Markandeya laid down the core theological framework that resulted in preventing future epidemics of water-borne diseases such as Cholera which were common in Java and Bali at the time of Markandey’s arrival in the area. The hydrological system devised and implemented by the sage, utilizing the burial of the calcined salts and hydroxides of the five sacred Metals, along the underground water supply aqueducts also enhanced the immunity of the population against other diseases such as malaria. Thus, the Ayurvedic and Siddha concepts of calcined sacred metals in preventing and curing diseases was utilized for public-health concerns—specifically, the need to control severe waterborne epidemics.

 

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

 

Previous Speakers

Prof. Buyong Ma

Shanghai Jiaotong University, China

Professor Buyong Ma has more than 25 years experiences in the computational studies of protein structure and function, protein engineering, and antibody-antigen recognition. He has proposed “conformation selection” theory which is widely used in explaining drug-target interaction. Dr. Ma received his Ph.D. in physical chemistry from the University of Georgia at Athens in 1995 and continued his postdoctoral training on computational chemistry. He joined NCI/NIH in 1998. In 2019, Dr. Ma accepted a tenured professor position in the school of pharmacy, Shanghai Jiaotong University, focusing on biological drug design. He has published more than 200 papers, with google citation of 21000 and H-index 66.

Prof. Walter Herzog

University of Calgary, Canada

Dr. Herzog did his undergraduate training in Physical Education at the Federal Technical Institute in Zurich, Switzerland (1979), completed his doctoral research in Biomechanics at the University of Iowa (USA) in 1985, and completed postdoctoral fellowships in Neuroscience and Biomechanics in Calgary, Canada in 1987. Currently, Dr. Herzog is a Professor of Biomechanics with appointments in Kinesiology, Medicine, Engineering, and Veterinary Medicine, holds the Canada Research Chair for Cellular and Molecular Biomechanics, and is appointed the Killam Memorial Chair for Inter-Disciplinary Research at the University of Calgary. His research interests are in musculoskeletal biomechanics with emphasis on mechanisms of muscle contraction focusing on the role of the structural protein titin, and the biomechanics of joints focusing on mechanisms of onset and progression of osteoarthritis. Dr. Herzog is the recipient of the Borelli Award from the American Society of Biomechanics, the Career Award from the Canadian Society for Biomechanics, the Dyson Award from the International Society of Biomechanics in Sports, the Muybridge Award from the International Society of Biomechanics, and recently received the Killam Prize in Engineering from the Canada Council for the Arts for his contributions to Biomedical research. He is the past president of the International, American and Canadian Societies for Biomechanics. He was inducted into the Royal Society of Canada in 2013.

Prof. Chang-Deng Hu

Purdue University, USA

Dr. Chang-Deng Hu is a Professor and Steve and Lee Ann Taglienti Chair in Pharmacy in the Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University College of Pharmacy. He also serves as Program Co-Leader of Cell Identify and Signaling and Program Co-Leader of Prostate Cancer Discovery Group in the Purdue University Center for Cancer Research. Dr. Hu received his M.D. from Bengbu Medical College, China and Ph.D. in molecular biology from Kobe University, Japan. Prior to his Ph.D. study, he also conducted his graduate study for M.S. degree in tumor immunology at Tongji Medical University, China. During his postdoctoral research at the University of Michigan, Dr. Hu pioneered the development of bimolecular fluorescence complementation (BiFC) technology for visualization of protein-protein interactions in live cells. His lab at Purdue has developed an integrated research program that involves technology development, biological discovery, and clinical translation. The current research focus in the lab is “Mechanism and targeting of therapy-induced neuroendocrine differentiation in prostate cancer.”

 

Assoc. Prof. Dan Li

Zhejiang University, China

Dan Li is an associated professor at the College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, P. R. China. She received her PhD degree in Biochemistry and Molecular Biology from Marburg University, Germany in 2009. She then worked as a postdoctoral fellow in the research group of Prof. Dr. Roland K. Hartmann (Institute of Pharmaceutical Chemistry, Philipps-UniversityMarburg, Germany) from 2009 to 2010, and then Alexander von Humboldt fellowship in the research group of Prof. Dr. Albrecht Bindereif (Institute of Biochemistry, Justus-Liebig-University Giessen, Germany) from 2010 to 2013. Her research work is now focusing on design and discovery of small new-scaffold bioactive compounds targeting innovative target sites, especially on drugs targeting nucleic receptor.